In summary, we have shown that AMPK activation is associated with good prognosis among MAPK3/1-activated colorectal cancer patients, while AMPK activation is not associated with prognosis among MAPK3/1-inactive cancer patients. This evidence concerns the gene PRKAA2 and colorectal cancer.